TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00792870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
Study: NCT01647672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane for neoadjuvant chemotherapy
Study: NCT03120533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iontophoresis of treprostinil
Description: the participant will receive 10 days of iontophoresis of treprostinil on a first site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoresis of placebo
Description: the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
Study: NCT02991027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI OCT Triton
Description: DRI OCT Triton using micro-electro-mechanical short cavity tunable laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI OCT Triton
Description: DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
Study: NCT04264923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HyGIeaCare Prep
Description: Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
Study: NCT02615977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zooming Joystick Task
Description: Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Zooming Joystick Task (Placebo)
Description: Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates.
Study: NCT03674671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
Study: NCT03214185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF/ICSI
Description: in vitro fertilization or intracytoplasmatic sperm injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: in vitro fertilization or intracytoplasmatic sperm injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGS 2.0
Description: Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional embryo morphology evaluation
Description: Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
Study: NCT04611932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D090 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D090 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D090 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T
Study: NCT03196882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg/day of iron
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg/day of iron
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg/day of iron
Description: Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
Study: NCT01898325

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Fibroscan

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Fibroscan

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Fibroscan

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Fibroscan
Study: NCT02789462

Intervention type: PROCEDURE
Intervention: Laser-assisted percutaneous coronary interventions
Description: Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
Study: NCT03856463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Navigator Intervention
Description: Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by local oncologists

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study: NCT03911856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Gas Exchange
Description: We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Gas Exchange
Description: We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
Study: NCT03000218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Ursodeoxycholic acid 300mg bid for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Ursodeoxycholic acid 300mg bid for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Day 29 to 56: Metformin 500mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 to 56: Placebo bid
Study: NCT00516009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXAMETHASONE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT03254030

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic inspection
Description: Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colonic inspection
Description: Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
Study: NCT03728218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses (Orthokeratology)
Description: Contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses (Soft Multifocal)
Description: Contact lenses
Study: NCT00729274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline solution
Description: Two 4ml nebulizations with 30 minute interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution
Description: Two 4ml nebulizations with 30 minute interval
Study: NCT02459496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting and advise
Description: first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting and advise
Description: first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
Study: NCT03760250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
Study: NCT03982472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electric stimulation
Description: transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electric stimulation
Description: transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
Study: NCT03530176

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18Fluoride-Sodium Fluoride radio-isotope
Description: The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
Study: NCT02011113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
Study: NCT01102062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange juice
Study: NCT01206114

Intervention type: OTHER
Intervention: Follow-up
Description: Questionnaires, interviews, nasal/oral and serum samples, register data

Intervention type: OTHER
Intervention: Follow-up
Description: Questionnaires, interviews, nasal/oral and serum samples, register data
Study: NCT00706095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
Study: NCT02129296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air filled balloon
Description: Balloon filled with air according to the manufacturing company orders

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioenteric BIB® balloon
Description: Balloon filled with saline and methylene blue according to the manufacturing company orders
Study: NCT03814616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine tetraphosphate 180mg:artesunate 60mg
Description: ACT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine tetraphosphate 180mg:artesunate 60mg
Description: ACT
Study: NCT03196882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg/day of iron
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
Study: NCT03814616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine tetraphosphate 180mg:artesunate 60mg
Description: ACT
Study: NCT02488330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
Study: NCT03702361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPRIV
Description: VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Study: NCT03880916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Study: NCT00787397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Sleep
Description: Cognitive Behavioral Therapy: 6 sessions of CBT
Study: NCT00522782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Budesonide
Description: Pulmicort Respules 0.5mg/2cc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide Analyzer
Description: Niox NO analyzer
Study: NCT02733081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified IUD Insertion
Description: IUD Insertion with no bimanual pelvic exam or uterine sounding.
Study: NCT02553928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (twice daily)
Study: NCT01885650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway Clearance Techniques
Study: NCT02376244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
Study: NCT04188249

Intervention type: DRUG
Intervention: Golimumab
Description: This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
Study: NCT02584712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Exercise Training
Description: This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
Study: NCT03762460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online eHealth tool
Description: Mobile-optimized online eHealth tool to support MBC.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Informational website
Description: Participants randomized to this group will receive information about online resources for mental health
Study: NCT02376244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care cardiac rehabilitation according to current guidelines
Study: NCT00575614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 1 mg o.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: o.d.
Study: NCT05363436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Providers had to prescribe 15 oxycodone pills to each patient discharge
Study: NCT00373048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine
Description: tablet, once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, once weekly
Study: NCT02281656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.
Study: NCT05225883

Intervention type: GENETIC
Intervention: GWAS
Description: This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.
Study: NCT01053533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines plus western therapy
Description: injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: western therapy
Description: supportive therapy and antivirus therapy when necessary
Study: NCT03190798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin 300mg
Description: Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Canagliflozin
Study: NCT01352208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9521
Description: oral
Study: NCT02415140

Intervention type: OTHER
Intervention: Rate of depression

Intervention type: OTHER
Intervention: Rate of depression
Study: NCT00151424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine 5-10mgBID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched against asenapine and olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10-20 mg QD